Clinical trials: URINATION DISORDERS
Menopause
The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health
This Phase II study is designed to evaluate the potential effects of a novel probiotic supplement on the severity of global menopause symptoms (e.g., psychological, somatic, urogenital symptoms) and on bone health in…
- Trial name
- MPS (NCT04001088)
- Testing
- Probiotic
- Where
- 5 sites in United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Lallemand Health Solutions
Proteinuria
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
The purpose of this study is to assess the effects of high doses of candesartan cilexetil and also to assess which dose (16mg, 64mg, 128mg) is the most optimal for the maximum reduction of proteinuria.
- Trial name
- NCT00242346
- Testing
- candesartan cilexetil
- Where
- 26 sites in Canada
- Volunteers
- 270 people
- Sponsor
- AstraZeneca
Urinary Incontinence, Urge Incontinence
UCon Treatment of Overactive Bladder (OAB) in Males
UCon is a medical device for treatment of the symptoms of OAB and fecal incontinence (FI). It electrically stimulates the DGN through the skin to obtain modulated behaviour of the bladder musculature e.g., suppress undesired…
- Conditions
- Urinary Incontinence, Urge Incontinence, Nocturia, Urinary Frequency More Than Once at Night
- Trial name
- NCT05874375
- Testing
- Urge stimulation, Time limited stimulation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- InnoCon Medical
Urinary Incontinence
Collection of Real-life Measurement Data for TENA SmartCare Change Indicator in Subjects With Urinary Incontinence
This study is an explorative, open, single-arm clinical investigation to collect real-life measurement data in order to assess the mathematical algorithms involved in TENA SmartCare Change Indicator.
- Trial name
- NCT04071301
- Testing
- TENA SmartCare Change Indicator
- Where
- Sweden
- Volunteers
- 15 people
- Sponsor
- Essity Hygiene and Health AB
Stress Urinary Incontinence
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT02658448
- Testing
- GTx-024
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- GTx
Chronic Kidney Disease, Diabetic Nephropathy
Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor
Prospective, Randomized, Double-Blind, Placebo-Controlled Multicenter Study. The objective of the study is to evaluate the efficacy and safety of once daily administration of atrasentan tablets (low dose and high dose) compared…
- Trial name
- RADAR (NCT01356849)
- Testing
- Atrasentan
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 149 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Urge Incontinence
Efficacy of Surface Electrical Stimulation for Urge Urinary Incontinence in Women
The purpose of this research is to evaluate the effectiveness of the ELITONE-UUI electrical muscle stimulation device on treating urge incontinence.
- Trial name
- NCT04752709
- Testing
- ELITONE UUI
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Elidah, Inc.
Stress Urinary Incontinence
Safety and Clinical Performance Study of the ARTUS® Artificial Urinary Sphincter (AUS)
This clinical investigation is designed as an interventional, prospective, non-randomized, open-label, single arm, multicentric and international study for obtaining CE marking.
- Trial name
- DRY (NCT04827199)
- Testing
- Artificial Urinary Sphincter implantation
- Where
- 3 sites in Czechia, Spain
- Volunteers
- 70 people
- Sponsor
- Myopowers Medical Technologies France SAS
Nocturnal Enuresis
MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis
Desmopressin in treatment of nocturnal enuresis (bedwetting).
- Trial name
- MELT (NCT01368913)
- Where
- 73 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Fabry Disease
Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients
The objective of this study is to increase the understanding surrounding the choices presented to patients and families impacted by Fabry disease.
- Trial name
- NCT04804566
- Testing
- This is a non-interventional study
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Amicus Therapeutics
Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI)
Augmenting Urinary Reflex Activity Study 4 (Including eXtended Indications)
Exploratory safety and feasibility study of personalized adaptive pudendal neuromodulation for mixed urinary incontinence and extended indications using an implanted (Picostim™ II) system.
- Conditions
- Mixed Urinary Incontinence, Stress Urinary Incontinence (SUI), Chronic Pelvic Pain, Urge Urinary Incontinence
- Trial name
- AURA-4X (NCT06885931)
- Testing
- Pudendal neuromodulation
- Where
- 7 sites in Belgium, Netherlands and 1 more
- Volunteers
- 86 people
- Sponsor
- Amber Therapeutics Ltd
Overactive Bladder
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.
- Trial name
- NCT00337090
- Testing
- YM178
- Where
- 84 sites in Belgium, Czechia and 13 more
- Volunteers
- 1,108 people
- Sponsor
- Astellas Pharma Inc
Vaginal Atrophy, Vulvovaginal Signs and Symptoms
Evaluation of the Efficacy and Safety of the Dermal Filler for Female Intimate Area Hydration and Atrophy of the Vagina.
The study is an open-label uncontrolled single-center study for the evaluation of the Performance characteristics (efficacy and safety) of the dermal filler "MMG-23-04-2019" on the female genital area for the medicinal…
- Conditions
- Vaginal Atrophy, Vulvovaginal Signs and Symptoms, Dyspareunia, Urinary Incontinence
- Trial name
- NCT04659668
- Testing
- MMG-23-04-2019
- Where
- Bulgaria
- Volunteers
- 37 people
- Sponsor
- Mesoestetic Pharma Group S.L.
Urinary Incontinence, Stress
Prospective US Radiofrequency SUI Trial
PURSUIT: Prospective US Radiofrequency SUI Trial (VI-17-06) is a prospective, randomized, sham controlled, double blind study in premenopausal women with stress urinary incontinence.
- Trial name
- PURSUIT (NCT04720352)
- Testing
- Active treatment
- Where
- 29 sites in United States
- Volunteers
- 390 people
- Sponsor
- Viveve Inc.
Sickle Cell Disease
SIKAMIC (SIklos on Kidney Function and AlbuMInuria Clinical Trial)
The purpose of this phase IIb, international, multicentre, double-blind, randomised, placebo-controlled study is to determine the effect of hydroxycarbamide on albuminuria after 6 months of treatment in SCD adult patients.
- Trial name
- SIKAMIC (NCT03806452)
- Testing
- Hydroxycarbamide
- Where
- 21 sites in Côte d’Ivoire, France and 4 more
- Volunteers
- 86 people
- Sponsor
- Theravia
Overactive Bladder
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
The purpose of this study is to determine the optimal dose of botulinum toxin type A injected in the detrusor muscle to improve urinary symptoms, urodynamic parameters and quality of life of continent women suffering from…
- Trial name
- NCT00578097
- Testing
- Botulinum toxin type A
- Where
- 34 sites in Belgium, Czechia and 6 more
- Volunteers
- 81 people
- Sponsor
- Ipsen
Stress Urinary Incontinence
Disposable Stress Urinary Incontinence Pessary Device Study
This study is an interventional, single arm, multi-center study. It will be conducted at sites in the northeastern United States. The protocol will be approved by Chesapeake IRB or applicable local IRBs.
- Trial name
- NCT03323723
- Testing
- SUI Device
- Where
- 3 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Rinovum Women's Health, Inc.
Chronic Kidney Disease, Proteinuria
HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
This study is to evaluate the renal function of HMG-CoA reductase add-on in chronic kidney disease patients with proteinuria.
- Trial name
- NCT03550859
- Testing
- Telmisartan/Rosuvastatin 40/10mg, Telmisartan 40mg
- Where
- 16 sites in South Korea
- Volunteers
- 374 people
- Sponsor
- Yuhan Corporation
Urinary Incontinence
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
- Trial name
- NCT00127270
- Testing
- Darifenacin, Behavioral therapy
- Where
- 67 sites in United States
- Volunteers
- 395 people
- Sponsor
- Novartis
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro